Catalyst Story

<div class='circular--portrait' style='background:#006400;color: #FFE4E1;font-size:4em;'>CB</div>
CBIO -- USA Stock  

USD 4.46  0.18  4.21%

Catalyst Biosciences Asset Turnover is quite stable at the moment as compared to the past year. The company's current value of Asset Turnover is estimated at 0.0268. Book Value per Share is projected to rise to 5.84 this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (56.5 M). Catalyst Biosciences is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 6th of August 2020. As some conservatives are trying to avoid healthcare space, we'll outline Catalyst Biosciences a little further and explain its current market possibilities. We will evaluate why we are still confident in anticipation of a recovery. Catalyst Biosciences odds of financial turmoil is under 6 percent. Will Catalyst Biosciences institutional investors continue to trade in September?
Published over a month ago
View all stories for Catalyst Biosciences | View All Stories
How Catalyst Biosciences (NASDAQ:CBIO) conflicting essential indicators helped with the latest slide?
Catalyst Biosciences secures Sharpe Ratio (or Efficiency) of -0.061, which signifies that the company had -0.061% of return per unit of risk over the last month. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Catalyst Biosciences exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Catalyst Biosciences mean deviation of 2.97, and Risk Adjusted Performance of (0.08) to double-check the risk estimate we provide.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Catalyst Biosciences income statement, its balance sheet, and the statement of cash flows. Potential Catalyst Biosciences investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Catalyst Biosciences investors may use each financial statement separately, they are all related. The changes in Catalyst Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Catalyst Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Catalyst Biosciences fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Catalyst Biosciences performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Catalyst Biosciences shares is the value that is considered the true value of the share. If the intrinsic value Catalyst is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Catalyst Biosciences. Please read more on our fundamental analysis page.

What is Catalyst Asset Breakdown?

Catalyst Biosciences reports assets on its Balance Sheet. It represents the amount of Catalyst resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Catalyst volatility, please check the breakdown of all its fundamentals

Are Catalyst Biosciences Earnings Expected to grow?

The future earnings power of Catalyst Biosciences involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Catalyst Biosciences factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Catalyst Biosciences stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Catalyst expected earnings.

Catalyst Biosciences Gross Profit

Catalyst Biosciences Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Catalyst Biosciences previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Catalyst Biosciences Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Catalyst Biosciences exotic insider transaction detected

Legal trades by Catalyst Biosciences insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Catalyst insider trading alert for general transaction of common stock by Howard Levy, Chief Medical Officer, on 12th of August 2020. This event was filed by Catalyst Biosciences Inc with SEC on 2020-08-12. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

An Additional Perspective On Catalyst Biosciences

Institutional investors typically avoid acquiring a high percentage of Catalyst Biosciences stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Catalyst is distributed among investors.

Ownership Allocation

Catalyst Biosciences retains a total of 22.05 Million outstanding shares. Over half of Catalyst Biosciences outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Catalyst Biosciences. Please watch out for any change in the institutional holdings of Catalyst Biosciences as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Retail Investors
40.42%
Insiders
5.59%
Institutions
53.99%
Retail Investors40.42
Insiders5.59
Institutions53.99

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Catalyst Biosciences has an asset utilization ratio of 23.55 percent. This suggests that the company is making $0.24 for each dollar of assets. An increasing asset utilization means that Catalyst Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
101.1 M
Current Assets101.07 Million97.44
Assets Non Current2.55 Million2.46
Goodwill101,5260.0979

Chances of Catalyst Biosciences institutional investors to go insane

The kurtosis is down to 1.51 as of today. Catalyst Biosciences exhibits very low volatility with skewness of -0.28 and kurtosis of 1.51. However, we advise investors to further study Catalyst Biosciences technical indicators to make sure all market info is available and is reliable.

Our Conclusion on Catalyst Biosciences

Whereas some other companies in the biotechnology industry are either recovering or due for a correction, Catalyst may not be as strong as the others in terms of longer-term growth potentials. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither pick up new shares of Catalyst nor exit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Catalyst Biosciences.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Catalyst Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com